Pharmacare for all: we cannot wait for the next health crisis - The Hill Times

Nfld. & LabradorNewfoundland and Labrador’s health minister says reaching a pharmacare deal with the federal government is one of his highest priorities. That comes despite the federal health minister's past statement that deals with other provinces will expire. PCs not giving up on federal pharmacare deal despite past minister's assertion the feds shut the doorMark Quinn · CBC News · Posted: Oct 01, 2026 4:30 AM EDT | Last Updated: October 1Listen to this articleEstimated 4 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Newfoundland and Labrador Health Minister Joedy Wall says signing on to the federal pharmacare program is a priority for the Progressive Conservative government. (Mark Quinn/ CBC)Newfoundland and Labrador's newly appointed health minister says reaching a pharmacare deal with the federal government is one of his highest priorities. "That was one of the top three things that was discussed when I came into the department was the pharmacare program," said Joedy Wall.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.